Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2

Cecylia S. Lupala, Vikash Kumar, Xuanxuan Li, Xiao‐Dong Su, Haiguang LiubioRxiv 2020 · DOI

TL;DR

This paper uses computational simulations to design and analyze short peptides derived from human ACE2 that can block SARS-CoV-2 from binding to host cells. The study identifies promising peptide candidates with strong binding affinities and stable structures, offering a foundation for developing new antiviral therapeutics.

What Problem Does This Paper Address?

The COVID-19 pandemic, caused by SARS-CoV-2, highlights the urgent need for effective antiviral treatments. A critical step in viral entry is the interaction between the SARS-CoV-2 spike protein's Receptor Binding Domain (RBD) and the human Angiotensin-Converting Enzyme 2 (hACE2) on host cells. Disrupting this interaction is a key therapeutic strategy. While full-length hACE2 has shown promise, its use as a drug is challenging. This paper explores the potential of using smaller, derived peptide fragments from hACE2 that can mimic its binding function but are more amenable to drug development. The challenge lies in identifying which specific peptide fragments are stable, maintain the necessary structural features for binding, and exhibit strong affinity to the viral RBD.

Methods

The researchers employed Molecular Dynamics (MD) simulations to investigate the behavior of designed peptides. They started with the crystal structure of the SARS-CoV-2 RBD bound to hACE2 to guide the design of nine short peptides (SIFs) derived from the N-terminal helix (α1) of hACE2. These SIFs varied in length from 12 to 70 residues.

The MD simulations were performed in two main scenarios:

  1. Peptides in free solution: To assess their structural stability and helical content.
  2. Peptides in complex with the SARS-CoV-2 RBD: To evaluate their binding affinity and the nature of their interactions.

Key simulation parameters and tools included:

  • CHARMM-GUI for system preparation.
  • GROMACS for running the MD simulations (300 ns for free peptides, 500 ns for complexes).
  • CHARMM36 force field for molecular modeling.
  • MM-GBSA (Molecular Mechanics with Generalized Born Surface Area) method to calculate binding energies.
  • RMSD (Root Mean Square Deviation) and RMSF (Root Mean Square Fluctuation) to analyze structural stability and conformational changes.
  • VMD and Chimera for visualization and analysis of interactions.

Datasets

Not discussed in the paper. The study primarily relies on computational simulations using existing structural data.

Key Insights and Ideas

  • Peptide design based on native structure is effective: By mimicking the helical structure of hACE2's N-terminal region, the designed peptides show potential for high binding affinity.
  • Helical content is crucial for binding: Peptides that maintain a higher helical content, both in free solution and when bound to the RBD, tend to have stronger binding affinities. This suggests that preserving the secondary structure is key to their function.
  • Specific residues are critical: Certain residues within the hACE2 N-terminal fragments (specifically residues 24-26 and 39-42) appear to play a significant role in stabilizing peptide binding to the RBD.
  • Short peptides can be unstable: While shorter peptides might seem attractive for drug development, some (like SIF8) showed significant instability and conformational changes, leading to dissociation from the RBD. This highlights the trade-off between peptide size and stability.
  • MD simulations provide mechanistic insights: The simulations not only quantified binding affinities but also revealed the molecular interactions (hydrogen bonds, van der Waals forces) at the peptide-RBD interface, offering explanations for observed binding behaviors.

Key Results

  • SIF3 and SIF4 showed high helical content (around 90% and 83% respectively in free form) and strong binding affinities (MM-GBSA energies of -90.43±14.16 kcal/mol and -67.33±18.08 kcal/mol, respectively).
  • SIF1 and SIF2 also demonstrated good helical content (62% and 68% free, 79% and 80% bound) and promising binding energies (-49.40±8.07 kcal/mol and -52.27±10.82 kcal/mol).
  • SIF8, a short peptide (12 residues), exhibited significant conformational instability in water and weak binding, consistent with previous experimental findings.
  • The study found a strong correlation between helical content and binding energy, with peptides having higher helical content generally showing stronger binding.

Limitations and Future Work

  • Computational limitations: The simulations, while extensive (up to 500 ns), represent a snapshot of the complex dynamics. Longer simulations might reveal further insights into stability and binding.
  • In vitro validation needed: The study is purely computational. Experimental validation of the designed peptides' efficacy in blocking SARS-CoV-2 binding and infection is the crucial next step.
  • Optimization of peptide sequences: While promising candidates were identified, further optimization of peptide sequences, particularly focusing on the identified critical residues and improving stability, could lead to even more potent inhibitors.
  • Peptidomimetic design: The authors suggest that these findings pave the way for designing peptidomimetics, which are molecules that mimic the structure and function of peptides but are often more stable and bioavailable. This is a clear direction for future research.

Summary updated

Abstract

ABSTRACT The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19, is spreading globally and has infected more than 3 million people. It has been discovered that SARS-CoV-2 initiates the entry into cells by binding to human angiotensin-converting enzyme 2 (hACE2) through the receptor binding domain (RBD) of its spike glycoprotein. Hence, drugs that can interfere the SARS-CoV-2-RBD binding to hACE2 potentially can inhibit SARS-CoV-2 from entering human cells. Here, based on the N-terminal helix α1 of human ACE2, we designed nine short peptides that have potential to inhibit SARS-CoV-2 binding. Molecular dynamics simulations of peptides in the their free and SARS-CoV-2 RBD-bound forms allow us to identify fragments that are stable in water and have strong binding affinity to the SARS-CoV-2 spike proteins. The important interactions between peptides and RBD are highlighted to provide guidance for the design of peptidomimetics against the SARS-CoV-2.
BibTeX
@misc{lupala2020computational,
  author = {Cecylia S. Lupala and Vikash Kumar and Xuanxuan Li and Xiao‐Dong Su and Haiguang Liu},
  title = {{Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2}},
  year = {2020},
  doi = {10.1101/2020.05.03.075473},
  howpublished = {bioRxiv},
}
Figure